Anticoagulants Market - By Drug Class (Factor Xa Inhibitors, Heparin), Route of Administration (Oral, Injectables), Application (Thromboembolism, Atrial Fibrillation, Coronary Artery Disease), Distribution Channel & Global Forecast, 2023

Description

List of Tables

Global Anticoagulants Market size will expand significantly through 2032. Rising awareness about early disease diagnosis is paving the path for market growth. Owing to growing awareness about disease diagnosis, governments across the globe are investing in screening programs and routine health check-ups to identify individuals at risk of developing blood clots and related disorders. Besides, product manufacturers are focusing on developing anticoagulants with advanced capabilities and maximum efficacy to strengthen their market position. These factors, in tandem, will propel anticoagulant sales over the coming years.

The overall anticoagulants market is classified based on drug category, route of administration, application, distribution channel, and region.

Based on the drug category, industry share from the heparin segment will grow at a lucrative CAGR from 2023 to 2032. Increasing prevalence of deep vein thrombosis, acute coronary syndrome, atrial fibrillation, pulmonary embolism, and other disorders that lead to blood clot formation has increased the need for heparin. As per the American Lung Association, pulmonary embolism is diagnosed in around 900,000 people every year in the U.S. alone.

Based on application, the anticoagulants market value from the atrial fibrillation/Flutter segment will register considerable gains through 2032. Growing occurrence of atrial fibrillation has increased the need for anticoagulants. As per CDC, over 454,000 hospital admissions with atrial fibrillation as the primary diagnosis take place every year in the U.S. Moreover, surging product approvals by regulatory bodies for the treatment of this disease are further working in favor of segment growth.

In terms of distribution channel, the hospital pharmacy segment amassed over 53.5% of the anticoagulants market share in 2022. The ease of availability of medicines at discounted prices has increased patient visits to hospital pharmacies. Moreover, growing investment by governments across the globe in hospital infrastructure has further increased the number of hospital pharmacies. These facilities offer patient-centered care and are equipped with cutting-edge medical equipment.

From the regional perspective, Europe anticoagulants market size will reach USD 14 billion by 2032. Growing geriatric population and its susceptibility to chronic ailments have bolstered the need for anticoagulants in the region. The high burden of heart diseases such as heart attack, stroke, and others has further increased product adoption in Europe. The region is also home to industry giants, such as Boehringer Ingelheim, Bayer AG, and others, emphasizing product innovations to stand out in the competition, which will support regional expansion.

Product Code: 4967

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Anticoagulants industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Drug category trends
- 2.1.4 Route of administration trends
- 2.1.5 Application trends
- 2.1.6 Distribution channel trends

Chapter 3 Anticoagulants Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of chronic disease
  - 3.2.1.2 Growing adoption of novel oral anticoagulants (NOACs)
  - 3.2.1.3 Rising geriatric population across the globe
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High risk of side effects
  - 3.2.2.2 Stringent regulatory framework
3.3 Growth potential analysis
- 3.3.1 By drug category
- 3.3.2 By route of administration
- 3.3.3 By application
- 3.3.4 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Anticoagulants Market Size and Forecast, By Drug Category (USD Million)

5.1 Key trends, by drug category
5.2 Factor Xa inhibitor
5.3 Heparin
5.4 Warfarin
5.5 Direct thrombin inhibitor
5.6 Others

Chapter 6 Anticoagulants Market Size and Forecast, By Route of Administration (USD Million)

6.1 Key trends, by route of administration
6.2 Oral
6.3 Injectable

Chapter 7 Anticoagulants Market Size and Forecast, By Application (USD Million)

7.1 Key trends, by application
7.2 Venous thromboembolism
7.3 Atrial fibrillation/flutter
7.4 Coronary artery disease
7.5 Others

Chapter 8 Anticoagulants Market Size and Forecast, By Distribution Channel (USD Million)

8.1 Key trends, by distribution channel
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy

Chapter 9 Anticoagulants Market Size and Forecast, By Region (USD Million)

9.1 Key trends, by region
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East & Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East & Africa

Chapter 10 Company Profiles

10.1 Bristol-Myers Squibb Company
10.2 Bayer AG
10.3 Boehringer Ingelheim
10.4 Johnson and Johnson
10.5 Daiichi Sankyo Company
10.6 Amphastar Pharmaceuticals, Inc.
10.7 Leo pharma
10.8 Pfizer
10.9 ROVI
10.10 Sanofi
10.11 Shenzhen Hepalink
10.12 United Therapeutics